[Complete and Prolonged Remission after a Single Dose of Venetocalx in a Patient with Acute Myeloid Leukemia (AML) Who Experienced Tumor Lysis Syndrome (TLS): Case Report].

The low-intensity treatment of acute myeloid leukemia (AML) with Venetoclax has led to a breakthrough in patients who cannot receive intensive chemotherapy. The combination of this drug with the hypomethylating agent (HMA) has yielded good results and low toxicity, but there is still a risk of side effects, including pancytopenia and the development of tumor lysis syndrome (TLS). This case report describes a patient with secondary AML that had transformed from chronic myelomonocytic leukemia (CMML) after the patient started initial treatment with these drugs, and developed a severe TLS syndrome, including the need for dialysis. However, the treatment was stopped after only one day and repeated tests found that the patient was in complete and prolonged remission from AML. This is a unique case of severe clinical TLS in a patient under this treatment regimen. Moreover, a prolonged and profound response after only a single day of partial treatment, as in this case, is unique and to the best of our knowledge there are no similar reports in the literature.